Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences ( (GILD) ) just unveiled an announcement.
At the 2026 annual meeting of stockholders held on April 30, 2026, Gilead Sciences’ investors elected nine directors to serve one‑year terms and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and adopted an amended and restated 2022 Equity Incentive Plan, reinforcing management’s compensation framework and long‑term incentive structure.
Shareholders voted down three stockholder proposals, rejecting an independent board chair policy, a report on the impact of extended patent exclusivities on patient access, and a report on risks related to ESG and DEI metrics in executive pay. These outcomes signal continued support for Gilead’s current board leadership model, patent and market‑exclusivity strategy, and approach to linking executive compensation with broader non‑financial performance measures, outcomes that may reassure management while disappointing some governance and social‑impact advocates.
The most recent analyst rating on (GILD) stock is a Hold with a $130.00 price target. To see the full list of analyst forecasts on Gilead Sciences stock, see the GILD Stock Forecast page.
Spark’s Take on GILD Stock
According to Spark, TipRanks’ AI Analyst, GILD is a Neutral.
The score is supported by strong current profitability and consistently robust free cash flow, reinforced by generally constructive guidance and pipeline catalysts from the latest earnings call. These positives are tempered by weak near-term technical momentum (downtrend/negative MACD despite oversold signals) and balance-sheet/leverage plus earnings-volatility concerns, with valuation appearing reasonable but not a standout.
To see Spark’s full report on GILD stock, click here.
More about Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for life‑threatening diseases, particularly in areas such as antiviral treatments and oncology. The company operates globally, with a business centered on innovative medicines that target unmet medical needs and support long‑term growth in the healthcare sector.
Average Trading Volume: 6,438,504
Technical Sentiment Signal: Buy
Current Market Cap: $163.4B
Find detailed analytics on GILD stock on TipRanks’ Stock Analysis page.